Verano Holdings (VRNO) Cash from Investing Activities (2021 - 2026)
Verano Holdings' (VRNO) quarterly Cash from Investing Activities came in at -$14.9 million in Q1 2026, down 212.45% year-on-year from $13.3 million in Q1 2025, and down 49.56% on a QoQ basis from -$10.0 million in Q4 2025.
Verano Holdings (VRNO) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Cash from Investing Activities data on file, last reported at -$14.9 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 212.45% year-over-year to -$14.9 million in Q1 2026; TTM through Mar 2026 was -$42.7 million, a 66.7% increase from a year earlier, with the FY2025 full-year figure at -$32.6 million, up 75.53% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$14.9 million, down from -$10.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for VRNO reached as high as -$4.8 million in Q1 2025 and fell as low as -$92.6 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$24.9 million across 5 years, with a median of -$10.4 million in 2025.
- Across the five-year window, Cash from Investing Activities surged 92.25% in 2023 and sank 830.65% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$22.6 million in 2022, then surged by 56.45% to -$9.8 million in 2023, then fell by 26.17% to -$12.4 million in 2024, then gained by 19.61% to -$10.0 million in 2025, then plunged by 49.56% to -$14.9 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$14.9 million in Q1 2026, -$10.0 million in Q4 2025, and -$7.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Verano Holdings | 2.01 Bn | 1.93 Bn | 98.98 Mn | -14.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.91 Mn |
| Mar 31, 2026 | -14.91 Mn |
| Dec 31, 2025 | -9.97 Mn |
| Dec 31, 2025 | -9.97 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -10.41 Mn |
| Jun 30, 2025 | -10.41 Mn |
| Mar 31, 2025 | -4.77 Mn |
| Mar 31, 2025 | -4.77 Mn |
| Dec 31, 2024 | -12.40 Mn |
| Dec 31, 2024 | -12.40 Mn |
| Sep 30, 2024 | -92.64 Mn |
| Sep 30, 2024 | -92.64 Mn |
| Jun 30, 2024 | -18.52 Mn |
| Jun 30, 2024 | -18.52 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Dec 31, 2023 | -9.83 Mn |
| Dec 31, 2023 | -9.83 Mn |